Journal
EXPERT REVIEW OF VACCINES
Volume 8, Issue 10, Pages 1399-1413Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.09.95
Keywords
antibody; anticancer vaccine; carbohydrate antigen; epitope; glycoconjugate; glycopeptide; mucin; oligosaccharide
Categories
Funding
- NIH [CA28824]
- NATIONAL CANCER INSTITUTE [R01CA028824, R37CA028824] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Malignantly transformed cells can express aberrant cell surface glycosylation patterns, which serve to distinguish them from normal cells. This phenotype provides an opportunity for the development of carbohydrate-based vaccines for cancer immunotherapy. Synthetic carbohydrate-based vaccines, properly introduced through vaccination of a subject with a suitable construct, should be recognized by the immune system. Antibodies induced against these carbohydrate antigens could then participate in the eradication of carbohydrate-displaying tumor cells. Advances in carbohydrate synthetic capabilities have allowed us to efficiently prepare a range of complex, synthetic anticancer vaccine candidates. We describe herein the progression of our longstanding carbohydrate-based anticancer vaccine program, which is now at the threshold of clinical evaluation in several contexts. Our carbohydrate-based anticancer vaccine program has evolved through a number of stages: monomeric vaccines, monomeric clustered vaccines, unimolecular multi-antigenic vaccines and dual-acting vaccines. This account will focus on our recently developed unimolecular multi-antigenic constructs and potential dual-acting constructs, which contain clusters of both carbohydrate and peptide epitopes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available